Funding transnational collaborative research through joint transnational calls is one of the major objectives of E-Rare. This is the most important and effective joint activity to enhance the cooperation between European scientists working on rare diseases and thus reducing the fragmentation of research in this field. E-Rare launches calls on a yearly basis. The topic and eligibility criteria are specified every year and therefore may vary from one call to the other.

Belgium
Switzerland
Germany
Canada
Cure-AID
IL-18 and MRP neutralization for the treatment of anti-IL-1-refractory autoinflammatory diseases

Project Coordinator

Ghent University
Ghent
Belgium

Partners

Johannes Roth Westfälische-Wilhelms-Universität Münster Muenster, Germany
Cem Gabay University Hospitals Geneva (UHG) Geneva, Switzerland
Paul Kubes University of Calgary (UofC) Calgary , Canada

Autoinflammatory diseases (AID) are a group of devastating systemic inflammatory syndromes characterized by seemingly unprovoked episodes of severe inflammation without signs of classical autoimmunity. The general prevalence of AID is below 1:100,000 individuals. As the genes mutated in AID are increasingly being mapped, inflammasome signalling and the cytoskeletal network are emerging as key mechanisms responsible for AID. Excess interleukin (IL)-1β production has a primary pathogenic role in select AID (exemplified by CAPS), but IL-1 neutralization therapies are ineffective or only partially effective in the majority of AID patients. Thus, there is a high, unmet need for development of novel therapies to treat IL-1-refractory AID and devastating AID-associated complications such as macrophage activation syndrome (MAS). Our consortium has classified a subset of AID patients with selective and highly elevated IL-18 and MRP8/14 in circulation. These inflammatory mediators are hypothesized to support a vicious inflammatory cycle in anti-IL1-refractory AID. The consortium has at its disposal a unique set of preclinical therapeutic agents, as well as cellular and in vivo models of non-classical AID, that will be exploited to address the therapeutic potential of IL-18 and MRP neutralization strategies in single and combination regimens. Finally, we will address how modulation of cytoskeleton dynamics and immune cell activation may affect IL-18 and MRP8/14 secretion as a therapeutic strategy in AID mouse models using cutting-edge in vivo imaging.

E-Rare 2012 - Created by Toussaint Biger